Clinical trial
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell…
NCT00251394 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00251394 |
|---|---|
| Title | Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma |
| Official title | A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma. |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Dynavax Technologies Corporation Industry James P. Wilmot Cancer Center University of Rochester Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Rituxan, 1018 ISS |
| Enrollment | 30 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Jul 1, 2009 |
| First posted | Nov 10, 2005 |
| Last update posted | Jan 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: